Between the Palais des Congrès in Paris (IMCAS, January 29–31) and the Grimaldi Forum in Monaco (AMWC, March 26–28), the aesthetic medicine community gathered in force — over 30,000 delegates at IMCAS alone, with AMWC welcoming 17,000 professionals from 140 countries. What emerged from both events was not a collection of product launches or incremental updates. It was, in every sense, a structural shift in how we think about what we do.
The word that echoed through every lecture hall, symposium, and corridor was regeneration. Not correction. Not filling. Regeneration.
From “Procedural Medicine” to “Tissue Performance Medicine”
For most of the past two decades, aesthetic medicine operated on a fundamentally reactive logic: a patient presents with volume loss, we restore it; lines appear, we relax them. The treatments were effective, but the philosophical framework was that of repair — intervening after the fact.
What IMCAS and AMWC 2026 have collectively made clear is that this framework is no longer adequate. The emerging paradigm is proactive: the goal is not to restore what the tissue has lost, but to optimise how it behaves going forward. Collagen density, cellular resilience, biological longevity — these are the new clinical endpoints. As one of the most consistent themes across both congresses summarised it, the industry has shifted “from adding volume to orchestrating biology.”
This is more than semantic. It changes what we prescribe, how we explain it to patients, and ultimately how we measure success.
Bioregenerators: The New Clinical Standard
The clearest expression of this new paradigm is the rise of bioregenerative treatments — and the scientific sophistication with which they are now being discussed.
Exosomes were among the dominant narratives at IMCAS, having moved firmly from experimental research into clinical protocols. Derived from Wharton’s Jelly (perinatal connective tissue), next-generation exosomal preparations carry over 1,000 growth factors and cytokines capable of transmitting repair signals to stressed cells — enabling uniform regeneration and accelerated intercellular communication. The pre-congress RAES (Regenerative Aesthetic Exosome Summit) held on January 28 in Paris was entirely dedicated to this topic, reflecting its ascent to a standalone discipline.
Polynucleotides (PDRN and high-molecular-weight variants) continued to attract scientific attention at both events, particularly in combined protocols targeting photoageing and skin texture. The key development in 2026 is the increasingly nuanced clinical use of these agents: rather than generic application, practitioners are now layering PDRN with other bioregenerators based on specific tissue deficit profiles.
Hybrid biostimulators — combining Calcium Hydroxylapatite and Poly-L-Lactic Acid (PLLA) — were highlighted at AMWC as tools for structural neocollagenesis. Galderma presented data at Monaco on the regenerative effects of PLLA, reinforcing that the goal is fibroblast activation and progressive tissue renewal, not volume substitution. The clinical relevance is significant: by addressing the underlying biological deficit rather than masking it, we substantially reduce the risk of what the literature increasingly calls “filler fatigue” — that telltale, unnatural stiffness that results from cumulative volumisation without tissue support.
Menopause: The Clinical Frontier We Can No Longer Ignore
One of the most substantive themes at IMCAS 2026 — spanning scientific sessions, symposia, and industry presentations alike — was menopause. This may surprise practitioners who still think of aesthetic medicine as primarily addressing aesthetic preferences. But the evidence is compelling, and the clinical opportunity is real.
Gerry Muhle, Head of Global Product Strategy at Galderma, presented data from a cohort of over 4,300 women that produced a striking finding: of all interventions assessed to manage menopause-related changes — including cognitive behavioural therapy, hormone replacement therapy, and physical exercise — aesthetic treatments delivered the highest level of patient satisfaction. Yet only 15% of women in the study had actually used them, largely because they were unaware of the dermatological consequences of oestrogen decline until they became visible.
Samantha Kerr, PhD, Chief Scientific Officer at Merz Aesthetics, was equally direct: collagen loss accelerates sharply during and after menopause, driven not only by declining systemic oestrogen but also by the skin’s reduced capacity to produce and respond to oestrogen locally. The implication for practice is clear — we should not be waiting for patients to present with visible signs. We should be initiating conversations about skin health at perimenopause, not after it.
Both Galderma and Merz Aesthetics announced they are now incorporating menopausal status into all clinical trials — a decision that will, over time, generate the evidence base needed to formalise this as a standard of care. For 2026, the practical message is straightforward: the menopause consultation is a core part of aesthetic medicine, not an optional add-on.
Energy-Based Devices: Precision, Combination, and an Unexpected New Entry
The energy-based device (EBD) space at both congresses reflected the same biological logic that governs injectables: less about surface correction, more about deep tissue stimulation.
Monopolar radiofrequency — notably at the 6.78 MHz gold-standard frequency — attracted renewed attention for its role in what is now being termed “collagen banking”: the proactive stimulation of collagen reserves in younger patients who want to preserve tissue quality over time, rather than restore it later. The integration of continuous water-cooling has made these protocols significantly more comfortable and suitable for a broader patient population.
Hybrid fractional lasers combining CO₂ and 1570nm wavelengths allow simultaneous treatment of the epidermal surface and the deep dermis — an efficiency that translates directly into better patient compliance and more consistent outcomes. Minimally invasive diode laser systems with ultra-fine fibres were highlighted by Dr. Sarolta Szabo at IMCAS as particularly effective for submental fat and skin laxity, with a precision that broader modalities cannot match.
The most unexpected development — and perhaps the one that most vividly illustrates how far the boundaries of aesthetic medicine are expanding — was the formal entry of Transcranial Magnetic Stimulation (TMS) into aesthetic practice. At IMCAS 2026, ExoMind, a non-invasive TMS technology designed to support neuroplasticity, was presented not as a curiosity but as a clinical tool. The reasoning is straightforward: chronic stress, poor sleep, and nervous system dysregulation are now recognised as direct drivers of skin ageing through cortisol-mediated inflammation. Addressing the neurological substrate is not fringe medicine — it is, as the IMCAS scientific programme framed it, the logical extension of treating the whole patient.
AI as Clinical Infrastructure
Artificial intelligence was present at both congresses not as a novelty but as operational infrastructure. The emphasis has shifted from AI as a marketing tool to AI as a diagnostic and documentation standard.
Facial analysis systems capable of objective, millimetre-precise assessments are enabling practitioners to quantify baseline tissue quality, track outcomes longitudinally, and communicate results to patients in terms they find credible and motivating. AMWC’s scientific sessions on personalised skincare algorithms and AI-driven treatment planning reflected a growing consensus: the practices that will define clinical excellence in the coming years are those that build data into their patient journey from the first consultation.
The Glossy Lip and the Death of Russian Lips
Not all the shifts were macroeconomic or biochemical. At the level of technique, one emblematic change crystallised the broader philosophical movement very neatly.
The “Russian Lips” technique — with its characteristic vertical projection and structured definition — has been formally displaced by what is now termed the “Glossy Lip”: an approach that prioritises deep hydration, natural turgidity, and luminosity over architectural projection or structural rigidity. It is, in microcosm, the aesthetic medicine of 2026 in a single treatment area: biological quality over geometric correction.
What This Means for Clinical Practice
The synthesis of IMCAS Paris and AMWC Monaco 2026 is not abstract. It translates into a set of concrete clinical priorities for the year ahead.
The language of consultation needs to evolve: terms like “anti-ageing” and “volume restoration” are being replaced by “longevity,” “skin resilience,” and “biological quality.” This is not branding — it accurately describes what the treatments are now designed to achieve.
Combined protocols are becoming the standard of care. Laser followed by exosomes, radiofrequency paired with PDRN, PLLA used as the biological scaffolding for subsequent HA work — the era of the single-modality session is giving way to orchestrated, multi-stage protocols designed around tissue biology rather than procedural convenience.
And perhaps most importantly: the scope of the consultation must expand. Menopausal status, metabolic health, GLP-1 use, stress load — these are all relevant clinical variables. The practitioner who integrates them into their diagnostic thinking will deliver outcomes that are, quite simply, better.
The congresses of 2026 did not announce the future of aesthetic medicine. They described its present.
